MetaCap

Apollomics (APLM) vs Milestone Pharmaceuticals (MIST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Apollomics (APLM) has outperformed Milestone Pharmaceuticals (MIST) over the past year, gaining 7.4% versus a loss of 84.5%. Over five years, MIST leads with a -93.8% price change compared with -98.4% for APLM. Milestone Pharmaceuticals is the larger company by market cap ($46.2 million vs $45.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APLM+7.43%MIST-84.54%
+103%+4%-94%
Nov 21, 20251 yearNov 20, 2026
APLM-98.43%MIST-93.85%
+157%+22%-112%
Nov 22, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APLM versus MIST key metrics
MetricAPLMMIST
Share price$15.54$0.3711
Market cap$45.28M$46.20M
1-day change-6.92%-7.06%
YTD return-16.90%-81.63%
1-year return+7.43%-84.54%
5-year return-98.43%-93.85%
EPS (TTM)$-0.25$-0.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-53.86M$-63.06M
52-week high$28.29$3.06
52-week low$12.58$0.362
Distance from 52-week high-45.09%-87.87%
Analyst consensus—none
Avg. price target upside—+1479.09%
Average volume11.07K1.53M
Shares outstanding2.91M124.50M
Employees1438
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • APLM has outperformed MIST by 92.0 percentage points over the past year.

About Apollomics

APLM stock →

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Milestone Pharmaceuticals

MIST stock →

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

APLM vs MIST FAQ

Which is bigger, Apollomics or Milestone Pharmaceuticals?

Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $46.20M compared with $45.28M for Apollomics (APLM).

Which stock has performed better over the past year, APLM or MIST?

APLM returned +7.43% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.

Are Apollomics and Milestone Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons